Approved indications: Zynrelef is approved for use in adults for a single instillation into the surgical site to provide postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures, including foot and ankle and other procedures where direct exposure of articular cartilage is avoided.

Off-label uses: Because the current U.S. indication already covers a broad range of soft tissue and orthopedic surgeries, off-label use is limited; use in highly vascular procedures (such as intrathoracic, large multilevel spinal, or head and neck surgery) is specifically not established and is generally avoided.

Efficacy expectations: Pain relief typically begins soon after surgery as the drug coats the tissues and continues for about 72 hours, when pain is usually most intense.

Clinical outcomes: In trials, Zynrelef has been shown to lower pain scores and reduce the proportion of patients needing opioids, with some patients requiring no opioids at all in the first 72 hours after surgery compared with standard bupivacaine solution.

Comparison with similar drugs: Versus conventional short-acting local anesthetic injections, Zynrelef offers longer-lasting analgesia from a single application; direct head-to-head data with other extended-release local anesthetics are limited, but overall it is used as part of multimodal, often opioid-sparing, postoperative pain regimens.

How it is given: Zynrelef is administered only by healthcare professionals as a single, needle-free instillation directly into tissues within the surgical site after final irrigation and suction and just before wound closure.

Typical dosing: The dose is chosen by the surgeon based on the type and size of the procedure, generally ranging from about 60 mg/1.8 mg up to a maximum of 400 mg bupivacaine/12 mg meloxicam (14 mL total volume) applied once to coat the affected tissues.

Administration details: It is for instillation use only and must not be injected into the spine (epidural or intrathecal), blood vessels, or used for regional nerve blocks or routine intra-articular injection; additional local anesthetics are usually avoided for at least 96 hours because their toxic effects can add up.

Special instructions: The product is prepared and applied using only the components supplied in the kit, following sterile technique; it is not mixed with saline, water, or other local anesthetics.

Use with food or timing: Because Zynrelef is given during surgery directly into the wound rather than taken by mouth, there are no special instructions about meals or time of day for patients to follow.

Missed dose: If Zynrelef is not used during surgery, it is not given later; pain is then managed with other medicines such as systemic analgesics or nerve blocks according to the care team’s plan.

Overdose: Too large a dose or inadvertent intravascular administration could lead to signs of local anesthetic toxicity (for example, ringing in the ears, metallic taste, numbness around the mouth, confusion, seizures, or heart rhythm changes) or more pronounced NSAID effects such as kidney problems or bleeding; treatment consists of immediate supportive care and standard measures for local anesthetic systemic toxicity and NSAID overdose in a monitored setting.

Common side effects: Frequently reported effects include constipation, vomiting, dizziness, headache, and symptoms around the surgical site such as swelling, redness, or delayed wound healing; these are usually mild to moderate and occur within the first few days after surgery.

Serious or rare adverse effects: Serious NSAID-related problems can include heart attack or stroke, high blood pressure, fluid retention, and gastrointestinal bleeding or ulcers; bupivacaine can, in rare cases, cause serious heart or nervous system toxicity (such as seizures or abnormal heart rhythms), and both components can rarely trigger severe allergic or skin reactions or a blood disorder called methemoglobinemia.

Warnings and precautions: Because Zynrelef contains meloxicam (an NSAID), it carries a boxed warning for increased risk of cardiovascular thrombotic events and serious gastrointestinal bleeding, and it must not be used in patients undergoing coronary artery bypass graft (CABG) surgery.

Special populations: Use is approved only in adults; safety and effectiveness in children have not been established.

Pregnancy and breastfeeding: Use after about 20 weeks of pregnancy can affect the fetus’s kidneys and heart (including premature closure of the ductus arteriosus), so it should be limited between about 20 and 30 weeks and avoided at 30 weeks and later; decisions in pregnancy and breastfeeding require an individualized risk–benefit discussion.

Kidney and liver disease: Because NSAIDs can worsen kidney function and fluid balance, Zynrelef should be avoided in severe kidney disease and used cautiously in patients with milder kidney or significant liver disease or those at high risk for bleeding.

Age and cardiovascular risk: Older adults and people with existing cardiovascular disease, high blood pressure, or prior peptic ulcer or GI bleeding have higher risks for NSAID-related complications and need careful assessment and monitoring.

Relative safety profile: Compared with giving high systemic doses of oral NSAIDs and opioids, Zynrelef delivers its components mostly locally with lower blood levels, which may reduce but does not eliminate systemic NSAID and local anesthetic risks; it should still be used with the same basic precautions as other bupivacaine and meloxicam products.

Reporting and safety updates: Patients and clinicians can report suspected side effects to the U.S. Food and Drug Administration (FDA) MedWatch program (online or by phone) and check the FDA website for ongoing safety communications about Zynrelef.

Other local anesthetics and related drugs: Because the toxic effects of local anesthetics are additive, Zynrelef should not be combined with additional bupivacaine products or other amide-type local anesthetics (such as lidocaine or ropivacaine) in doses that could increase systemic levels, and caution is needed with certain antiarrhythmic drugs that have similar cardiac effects.

NSAIDs, aspirin, and blood thinners: The meloxicam component can increase bleeding risk, so concurrent use of other NSAIDs, high-dose aspirin, anticoagulants (for example warfarin or direct oral anticoagulants), or antiplatelet agents (such as clopidogrel) requires caution and careful assessment of bleeding risk.

Blood pressure and kidney medicines: As with other NSAIDs, Zynrelef may reduce the effect of ACE inhibitors, ARBs, and some diuretics and may increase the risk of kidney impairment when used in patients taking these drugs, especially if they are volume-depleted or have preexisting kidney disease.

Other potential NSAID interactions: Systemic meloxicam exposure from Zynrelef is lower than with oral dosing but still warrants caution with drugs such as lithium or high-dose methotrexate, where NSAIDs can raise blood levels or toxicity.

Alcohol and food: No specific food interactions are known, but drinking alcohol around the time of surgery can further increase the risk of stomach irritation and bleeding associated with NSAIDs.

Medical conditions needing caution: Use is generally avoided or used with great caution in patients with a history of severe NSAID allergy or aspirin-sensitive asthma, active or recent GI ulcers or bleeding, severe kidney disease, uncontrolled heart failure, or recent major cardiovascular events, and it is contraindicated for CABG surgery and obstetric paracervical block.

Pregnancy and breastfeeding precautions: Because of NSAID-related fetal risks after about 20 weeks of gestation, Zynrelef should be used during pregnancy only when clearly needed and is typically avoided in the later third of pregnancy; decisions about use while breastfeeding are individualized, balancing potential benefits of improved maternal pain control with the low but possible systemic exposure of the infant.

Monitoring needs: During and after surgery, clinicians monitor vital signs, mental status, and the surgical site for signs of local anesthetic toxicity, bleeding, kidney or cardiovascular problems, or allergic reactions, and may order blood tests in higher-risk patients as part of routine postoperative care.

Q: What is Zynrelef and when is it given?
A: Zynrelef is a combination of a long-acting numbing medicine (bupivacaine) and an anti-inflammatory pain reliever (meloxicam) that your surgeon applies directly into the surgical site at the end of the operation to help control pain for about three days.

Q: Is Zynrelef an opioid or will I still need opioid pain pills?
A: Zynrelef is not an opioid; it is a local anesthetic plus an NSAID, and while many patients need fewer or no opioid tablets after surgery, some people may still require additional pain medicine depending on their procedure and individual pain response.

Q: How long does the pain relief from Zynrelef last?
A: The medicine is designed to release slowly from the surgical site and typically provides meaningful pain relief for up to 72 hours after surgery, which is when pain is usually most intense.

Q: Are there any risks or side effects I should watch for after receiving Zynrelef?
A: Most side effects are mild, such as constipation, nausea, headache, or swelling at the incision, but you should seek urgent care if you develop chest pain, trouble breathing, severe stomach pain or black stools, sudden weakness or slurred speech, or signs of a serious allergic reaction like hives, wheezing, or swelling of the face or throat.

Q: Can I receive Zynrelef if I have heart disease, ulcers, or kidney problems?
A: Because Zynrelef contains an NSAID, people with a history of heart attack or stroke, significant heart failure, stomach or intestinal ulcers or bleeding, or serious kidney disease may not be good candidates, so it is important to tell your surgical team your full medical history before they decide whether to use it.

Q: Does Zynrelef interact with my regular medications?
A: Zynrelef can interact with certain drugs such as blood thinners, other NSAIDs or aspirin, some blood pressure and kidney medicines, and other local anesthetics, so always provide an up-to-date list of all prescription, over-the-counter, and herbal products you take before surgery.

Storage: Zynrelef kits are stored by hospitals or surgical centers at controlled room temperature (about 68°F to 77°F), with limited excursions between 59°F and 86°F, in their original packaging protected from light and moisture.

Patient handling: Patients do not take Zynrelef at home; it is prepared and used only in the operating room, so you will not need to store it yourself.

Disposal: Any unused Zynrelef and used supplies are discarded as medical waste by healthcare staff according to facility and regulatory requirements; patients do not need to manage disposal.